Reference is made to the stock exchange notice of Aqua Bio Technology ASA (the "Company") dated 30 August 2019, regarding expiry of the exercise period for the warrants issued by the Company pursuant to the general meeting's resolution on 7 January 2019 (the "Warrants").

At the expiry of the exercise period for the Warrants, the Company had received notice of exercise of 3,609,277 Warrants, which imply that the Company has issued 3,609,277 new shares, each with a par value of NOK 2.50, and that the share capital of the Company is increased with NOK 9,023,192.50.

The share capital increase pertaining to the exercise of the Warrants has now been registered in the Norwegian Register of Business Enterprises. The new share capital of the Company is NOK 38,420,427.50 divided by 15,368,171 shares, each with a par value of NOK 2.50. The new shares will be admitted to trading on Oslo Axess as soon as possible under ticker "ABT".

For further information, please contact Espen Kvale, acting CEO, telephone +47 916 28 092 or espen.kvale@aquabiotech.no

Aqua Bio Technology (ABT) is developing and commercializing sustainable biotechnology for use in skin care products. ABT's cosmetics ingredients are highly effective and they provide the cosmetics industry with natural alternatives to traditional ingredients. ABT is also marketing and distributing natural skin care products developed by partners towards consumers and professional users. Aqua Bio Technology is listed on the Axess market of the Oslo Stock Exchange.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.